A HIV Vaccine Proves Elusive Again As J&J Study Fails
Virus Continues To Evade Vaccine Developers
Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.
You may also be interested in...
Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
The Cambridge, MA-based biotech has one blockbuster-tipped drug already on the market, with another in pivotal studies.